ArticleNature communications2021
Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Large-scale drug sensitivity, gene dependency, and proteogenomic analyses of telomere maintenance mechanisms in cancer cells.Nature communications · 2025Article
- Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.Acta neuropathologica communications · 2025Article
- Telomere-metabolism-immunity axis in sarcoma: Immune evasion mechanisms and therapeutic strategies.Clinical and translational medicine · 2025Review
- Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma.NPJ precision oncology · 2025Article
- Telomere Maintenance Pathways in Lower-Grade Gliomas: Insights from Genetic Subtypes and Telomere Length Dynamics.International journal of molecular sciences · 2025Article
- Elevated reactive oxygen species can drive the alternative lengthening of telomeres pathway in ATRX-null cancers.Nucleic acids research · 2025Article
- Targeting ATR in patients with cancer.Nature reviews. Clinical oncology · 2024Review
- Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay.Frontiers in oncology · 2024Article
- Distinct characteristics of two types of alternative lengthening of telomeres in mouse embryonic stem cells.Nucleic acids research · 2023Article
- A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content.NPJ genomic medicine · 2023Article
- Article
- Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications.Cancers · 2023Article
- Highlighting vulnerabilities in the alternative lengthening of telomeres pathway.Current opinion in pharmacology · 2023Review
- NPCs and APBs: two HUBs of non-canonical homology-based recombination at telomeres?Cell cycle (Georgetown, Tex.) · 2023Article
- Hyperextended telomeres promote formation of C-circle DNA in telomerase positive human cells.The Journal of biological chemistry · 2023Article
- Review
- The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT).Cancers · 2023Review
- Amplification and Quantitation of Telomeric Extrachromosomal Circles.Bio-protocol · 2023Article
- Hyperextended telomeres promote C-circle formation in telomerase positive human cells.bioRxiv : the preprint server for biology · 2023Article
- TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.EMBO molecular medicine · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.